233 related articles for article (PubMed ID: 21690491)
1. Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone.
Zhang X; Zhang R; Raab S; Zheng W; Wang J; Liu N; Zhu T; Xue L; Song Z; Mao J; Li K; Zhang H; Zhang Y; Han C; Ding Y; Wang H; Hou N; Liu Y; Shang S; Li C; Sebokova E; Cheng H; Huang PL
Circulation; 2011 Jul; 124(1):77-86. PubMed ID: 21690491
[TBL] [Abstract][Full Text] [Related]
2. The metabolic basis of atherogenic dyslipidemia.
Vinik AI
Clin Cornerstone; 2005; 7(2-3):27-35. PubMed ID: 16473258
[TBL] [Abstract][Full Text] [Related]
3. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Syndrome During Menopause.
Mumusoglu S; Yildiz BO
Curr Vasc Pharmacol; 2019; 17(6):595-603. PubMed ID: 30179134
[TBL] [Abstract][Full Text] [Related]
5. Reassessing the cardiovascular risks and benefits of thiazolidinediones.
Zinn A; Felson S; Fisher E; Schwartzbard A
Clin Cardiol; 2008 Sep; 31(9):397-403. PubMed ID: 18781598
[TBL] [Abstract][Full Text] [Related]
6. Geraniol, alone and in combination with pioglitazone, ameliorates fructose-induced metabolic syndrome in rats via the modulation of both inflammatory and oxidative stress status.
Ibrahim SM; El-Denshary ES; Abdallah DM
PLoS One; 2015; 10(2):e0117516. PubMed ID: 25679220
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Syndrome in Children and Adolescents: Is There a Universally Accepted Definition? Does it Matter?
Serbis A; Giapros V; Galli-Tsinopoulou A; Siomou E
Metab Syndr Relat Disord; 2020 Dec; 18(10):462-470. PubMed ID: 32795106
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.
Pfützner A; Schneider CA; Forst T
Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):445-59. PubMed ID: 16918264
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone does not improve insulin signaling in mice with GH over-expression.
Gesing A; Bartke A; Masternak MM
J Endocrinol; 2013 Nov; 219(2):109-17. PubMed ID: 23946430
[TBL] [Abstract][Full Text] [Related]
11. Central obesity is important but not essential component of the metabolic syndrome for predicting diabetes mellitus in a hypertensive family-based cohort. Results from the Stanford Asia-pacific program for hypertension and insulin resistance (SAPPHIRe) Taiwan follow-up study.
Lee IT; Chiu YF; Hwu CM; He CT; Chiang FT; Lin YC; Assimes T; Curb JD; Sheu WH
Cardiovasc Diabetol; 2012 Apr; 11():43. PubMed ID: 22537054
[TBL] [Abstract][Full Text] [Related]
12. Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.
Fujitaka K; Otani H; Jo F; Jo H; Nomura E; Iwasaki M; Nishikawa M; Iwasaka T
Endocr J; 2011; 58(6):425-32. PubMed ID: 21498915
[TBL] [Abstract][Full Text] [Related]
13. Prediction of incident hypertension and arterial stiffness using the non-insulin-based metabolic score for insulin resistance (METS-IR) index.
Bello-Chavolla OY; Antonio-Villa NE; Vargas-Vázquez A; Martagón AJ; Mehta R; Arellano-Campos O; Gómez-Velasco DV; Almeda-Valdés P; Cruz-Bautista I; Melgarejo-Hernandez MA; Muñoz-Hernandez L; Guillén LE; Garduño-García JJ; Alvirde U; Ono-Yoshikawa Y; Choza-Romero R; Sauque-Reyna L; Garay-Sevilla ME; Malacara-Hernandez JM; Tusié-Luna MT; Gutierrez-Robledo LM; Gómez-Pérez FJ; Rojas R; Aguilar-Salinas CA
J Clin Hypertens (Greenwich); 2019 Aug; 21(8):1063-1070. PubMed ID: 31318156
[TBL] [Abstract][Full Text] [Related]
14. The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats.
Zanchi A; Perregaux C; Maillard M; Cefai D; Nussberger J; Burnier M
Am J Physiol Endocrinol Metab; 2006 Dec; 291(6):E1228-34. PubMed ID: 16835400
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone reverses insulin resistance and impaired CCK-stimulated pancreatic secretion in eNOS(-/-) mice: therapy for exocrine pancreatic disorders?
Reddy RC; Hao Y; Lee SH; Gangireddy SR; Owyang C; DiMagno MJ
Am J Physiol Gastrointest Liver Physiol; 2007 Jul; 293(1):G112-20. PubMed ID: 17510194
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid treatment facilitates development of a metabolic syndrome in ovariectomized Macaca Mulatta fed a high fat diet.
Li L; Yang G; Liao G; Mei J; Li L; Wang C; Yuan Y; Shi Y; Liu J; Zhong Z; Cheng J; Lu Y; Clarke IJ; Chen Y
Steroids; 2017 Dec; 128():105-113. PubMed ID: 28988119
[TBL] [Abstract][Full Text] [Related]
17. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W
Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
Derosa G; Maffioli P
Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
[TBL] [Abstract][Full Text] [Related]
19. Metabolic and additional vascular effects of thiazolidinediones.
Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance and its treatment by thiazolidinediones.
Lebovitz HE; Banerji MA
Recent Prog Horm Res; 2001; 56():265-94. PubMed ID: 11237217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
